vita	CORE <sup>®</sup> Pharmac	y: Phone:			
11	City/State/Zip: Email:				
Dermatology Referral Form					
Loot Nomo:	Please attach copy of insurance cards (front and back)       ne:     First Name:     DOB:     Practice:				
Last Name:	First Name		Address:		
Address:	Otatai				
City:	State: Zip: Sex: MOF City:		te: Zip	).	
Phone:					
Insurance Information Prescriber NPI: Insurance Plan: Insurance Plan: Nurse/Key Contact:					
Policy #:	Policy #: Phone:				
			Email:		
Plan #:					
		inical Information – Statement Of Medical Necessity ttach clinical/progress notes, labs, test supporting primary diagnosis			
Diagnosis:       L40.8 Moderate to severe plaque psoriasis       L40.50 Psoriatic arthritis       L73.2 Hidradenitis suppurativa         Diagnosis:       L20.9 Atopic dermatitis       Other       Other					
Prescription Information					
Medication	Dose/Strength	Directions	Quantity	Refills	
Adalimumab	□ Psoriasis starter kit □ 40mg pen □ 40mg PFS	Initial: Inject 80mg SC on day 1, 40mg on day 8, then maintenance dose every other week thereafter	1 starter kit		
	Psoriasis starter kit CF         40mg CF pen       40mg CF PFS		28-day supply		
Cimzia	□ 200mg vial kit	□ Initial: Inject 400mg SC at weeks 0, 2 and 4 □ Maintenance: Inject 400mg SC every 2 weeks			
□ 150mg Sensoready pen		Initial: Inject	28-day supply	0	
Cosentyx		Maintenance: Inject D 300mg or D 150mg SC every 4 weeks			
Dupixent	<ul> <li>200mg/1.14mL prefilled pen</li> <li>200mg/1.14mL prefilled syringe</li> <li>300mg/2mL prefilled pen</li> <li>300mg/2mL prefilled syringe</li> </ul>	Adults and pediatric ≥ 60kg:       600 mg (two 300 mg injections) followed by 300 mg every 2 weeks         Pediatric Patients <60kg	28-day supply		
Enbrel	□50mg SureClick autoinjector □50mg PFS □50mg mini □25mg PFS □25mg vials	<ul> <li>☐ Initial: RA/PsA 50mg</li> <li>☐ Initial: PsO 50mg twice weekly x 3 months</li> <li>☐ Maintenance: ped PsO/JPsA 0.8mg/kg weekly-max 50mg weekly</li> </ul>	28-day supply		
Humira	HS starter Kit □40mg pen □40mg PFS □HS starter kit CF	Initial: Inject 160mg SC on day 1, 80mg on day 15, then 40mg every week beginning on day 29	1 starter kit		
HS	□ 40mg CF pen □ 40mg CF PFS □ 80mg CF pen	<ul> <li>Maintenance: (At week 4) Inject 40mg SC weekly</li> <li>Inject 80mg every other week</li> </ul>	28-day supply		
llumya	100mg PFS	□ Inject 100mg at weeks 0, 4 and every 12 weeks thereafter			
Infliximab	100mg vial	□ Infuse 5mg/kg at 0, 2 and 6 weeks, then every 8 weeks			
Simponi	□ 50mg SmartJect □ 50mg PFS	□ Inject 50mg SC once a month as directed	28-day supply		
Skyrizi	<ul> <li>☐ 75mg 2 PFS kit</li> <li>☐ 150mg pen</li> <li>☐ 150mg PFS</li> </ul>	<ul> <li>Initial: Inject 150mg SC on week 0 and 4</li> <li>Maintenance: Inject 150mg SC every 12 weeks</li> </ul>	1	0	
Stelara	□ 45mg vial	<ul> <li>(&lt;220 lbs) Inject 45mg on day 0 then week 4, followed by 45mg dose every 12 weeks</li> <li>(&gt;220 lbs) Inject 90mg on day 0 then week 4, followed by 90mg dose every 12 weeks</li> </ul>	28-day supply		
Taltz	<ul> <li>80mg autoinjector pen</li> <li>80mg prefilled syringe</li> </ul>	<ul> <li>Initial: Inject 160mg SC at week 0 then 80mg at weeks 2, 4, 6, 8, 10 and 12</li> <li>Maintenance: Inject 80mg SC every 4 weeks</li> </ul>	28-day supply 28-day supply		
Tremfya	<ul> <li>Interview of the second second</li></ul>	Initial: Inject 100mg SC at week 0 and 4	20 ddy odppry	0	
	100mg prefilled syringe	Maintenance: Inject 100mg SC every 8 weeks	1		
Other					
Ship medications to: D Physician's clinic D Patient's home Injection training needed:			🗆 Yes 🛛	] No	

I authorize Vital Care Infusion Services LLC and its representatives to initiate any insurance prior authorization process that is required for this prescription and for any future refills of the same prescription for the patient listed above that I order. Date: \_ I understand that I can revoke this designation at any time by providing written notice to Vital Care.

Physician Signature: \_\_\_\_

PRESCRIBER MUST MANUALLY SIGN. STAMP SIGNATURE, SIGNATURE BY OTHER PERSONNEL AND COMPUTER-GENERATED SIGNATURES WILL NOT BE ACCEPTED. The attached document(s) contain confidential information which may be considered to be Protected Health Information and therefore required to be maintained as private and secure under HIPAA. The documents may also contain information which is otherwise considered to be privileged under state and federal laws. This communication is for the intended recipient only. If you are not the intended recipient, or a person responsible for delivering this communication to the intended recipient, you are prohibited from viewing, copying and/ or distributing the information contained herein. Unlawful disclosure of the information attached may subject you to monetary penalties and sanctions. If you have received this communication in error, you should notify the sender immediately and thereafter permanently destroy all copies of this document in its entirety.